Roche (SIX: RO, ROG;OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed a  COVID-19 test for researchers that detects and differentiates the latest subvariant of interest BA.2.75. The test specifically targets two of the known unique mutations in BA.2.75, which allows clear differentiation against other notable subvariants. “Roche is pleased to have developed a test for researchers that provides insights into the epidemiology of BA.2.75, helping to understand its impact on public health,” said Cindy Perettie, Head...